(Q48096783)

English

Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Long-term efficacy and safety of the interleukin-1 inhibitors anakinra and canakinumab in refractory Behçet disease uveitis and concomitant bladder papillary carcinoma. (English)

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Behçet's disease

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Claudia Fabiani

object named as

Claudia Fabiani

5

0 references

Giuseppe Lopalco

4

object named as

Giuseppe Lopalco

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

3

object named as

Donato Rigante

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

author name string

Ida Orlando

1

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Antonio Vitale

2

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

publication date

1 September 2017

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Internal Medicine Journal

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

47

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

9

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

1086-1088

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Efficacy and safety profile of anti-interleukin-1 treatment in Behçet's disease: a multicenter retrospective study

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Why not treat human cancer with interleukin-1 blockade?

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Anti-TNF- therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Anakinra treatment in drug-resistant Behcet’s disease: a case series

1 reference

https://api.crossref.org/works/10.1111%2FIMJ.13538

21 January 2018

Identifiers

10.1111/IMJ.13538

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

1 reference

Europe PubMed Central

8 February 2018

http://europepmc.org/abstract/MED/28891187

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48096783&oldid=1740065603"